357 related articles for article (PubMed ID: 34875674)
1. Multi-omic machine learning predictor of breast cancer therapy response.
Sammut SJ; Crispin-Ortuzar M; Chin SF; Provenzano E; Bardwell HA; Ma W; Cope W; Dariush A; Dawson SJ; Abraham JE; Dunn J; Hiller L; Thomas J; Cameron DA; Bartlett JMS; Hayward L; Pharoah PD; Markowetz F; Rueda OM; Earl HM; Caldas C
Nature; 2022 Jan; 601(7894):623-629. PubMed ID: 34875674
[TBL] [Abstract][Full Text] [Related]
2. Genomic characterization of HER2-positive breast cancer and response to neoadjuvant trastuzumab and chemotherapy-results from the ACOSOG Z1041 (Alliance) trial.
Lesurf R; Griffith OL; Griffith M; Hundal J; Trani L; Watson MA; Aft R; Ellis MJ; Ota D; Suman VJ; Meric-Bernstam F; Leitch AM; Boughey JC; Unzeitig G; Buzdar AU; Hunt KK; Mardis ER
Ann Oncol; 2017 May; 28(5):1070-1077. PubMed ID: 28453704
[TBL] [Abstract][Full Text] [Related]
3. Digital image analysis and machine learning-assisted prediction of neoadjuvant chemotherapy response in triple-negative breast cancer.
Fisher TB; Saini G; Rekha TS; Krishnamurthy J; Bhattarai S; Callagy G; Webber M; Janssen EAM; Kong J; Aneja R
Breast Cancer Res; 2024 Jan; 26(1):12. PubMed ID: 38238771
[TBL] [Abstract][Full Text] [Related]
4. Magnetic resonance imaging radiomics predicts preoperative axillary lymph node metastasis to support surgical decisions and is associated with tumor microenvironment in invasive breast cancer: A machine learning, multicenter study.
Yu Y; He Z; Ouyang J; Tan Y; Chen Y; Gu Y; Mao L; Ren W; Wang J; Lin L; Wu Z; Liu J; Ou Q; Hu Q; Li A; Chen K; Li C; Lu N; Li X; Su F; Liu Q; Xie C; Yao H
EBioMedicine; 2021 Jul; 69():103460. PubMed ID: 34233259
[TBL] [Abstract][Full Text] [Related]
5. SPAG5 as a prognostic biomarker and chemotherapy sensitivity predictor in breast cancer: a retrospective, integrated genomic, transcriptomic, and protein analysis.
Abdel-Fatah TMA; Agarwal D; Liu DX; Russell R; Rueda OM; Liu K; Xu B; Moseley PM; Green AR; Pockley AG; Rees RC; Caldas C; Ellis IO; Ball GR; Chan SYT
Lancet Oncol; 2016 Jul; 17(7):1004-1018. PubMed ID: 27312051
[TBL] [Abstract][Full Text] [Related]
6. Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer.
Prat A; Guarneri V; Pascual T; Brasó-Maristany F; Sanfeliu E; Paré L; Schettini F; Martínez D; Jares P; Griguolo G; Dieci MV; Cortés J; Llombart-Cussac A; Conte B; Marín-Aguilera M; Chic N; Puig-Butillé JA; Martínez A; Galván P; Tsai YH; González-Farré B; Mira A; Vivancos A; Villagrasa P; Parker JS; Conte P; Perou CM
EBioMedicine; 2022 Jan; 75():103801. PubMed ID: 34990895
[TBL] [Abstract][Full Text] [Related]
7. Quantitative digital histopathology and machine learning to predict pathological complete response to chemotherapy in breast cancer patients using pre-treatment tumor biopsies.
Saednia K; Lagree A; Alera MA; Fleshner L; Shiner A; Law E; Law B; Dodington DW; Lu FI; Tran WT; Sadeghi-Naini A
Sci Rep; 2022 Jun; 12(1):9690. PubMed ID: 35690630
[TBL] [Abstract][Full Text] [Related]
8. Machine learning models based on immunological genes to predict the response to neoadjuvant therapy in breast cancer patients.
Chen J; Hao L; Qian X; Lin L; Pan Y; Han X
Front Immunol; 2022; 13():948601. PubMed ID: 35935976
[TBL] [Abstract][Full Text] [Related]
9. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
[TBL] [Abstract][Full Text] [Related]
10. HER2DX genomic test in HER2-positive/hormone receptor-positive breast cancer treated with neoadjuvant trastuzumab and pertuzumab: A correlative analysis from the PerELISA trial.
Guarneri V; Bras-Maristany F; Dieci MV; Griguolo G; Par L; Mar Ín-Aguilera M; Miglietta F; Bottosso M; Giorgi CA; Blasco P; Castillo O; Galv N P; Vivancos A; Villagrasa P; Parker JS; Perou CM; Conte P; Prat A
EBioMedicine; 2022 Nov; 85():104320. PubMed ID: 36374768
[TBL] [Abstract][Full Text] [Related]
11. Machine learning classification of texture features of MRI breast tumor and peri-tumor of combined pre- and early treatment predicts pathologic complete response.
Hussain L; Huang P; Nguyen T; Lone KJ; Ali A; Khan MS; Li H; Suh DY; Duong TQ
Biomed Eng Online; 2021 Jun; 20(1):63. PubMed ID: 34183038
[TBL] [Abstract][Full Text] [Related]
12. PROACTING: predicting pathological complete response to neoadjuvant chemotherapy in breast cancer from routine diagnostic histopathology biopsies with deep learning.
Aswolinskiy W; Munari E; Horlings HM; Mulder L; Bogina G; Sanders J; Liu YH; van den Belt-Dusebout AW; Tessier L; Balkenhol M; Stegeman M; Hoven J; Wesseling J; van der Laak J; Lips EH; Ciompi F
Breast Cancer Res; 2023 Nov; 25(1):142. PubMed ID: 37957667
[TBL] [Abstract][Full Text] [Related]
13. Development of a machine learning-based radiomics signature for estimating breast cancer TME phenotypes and predicting anti-PD-1/PD-L1 immunotherapy response.
Han X; Guo Y; Ye H; Chen Z; Hu Q; Wei X; Liu Z; Liang C
Breast Cancer Res; 2024 Jan; 26(1):18. PubMed ID: 38287356
[TBL] [Abstract][Full Text] [Related]
14. Impact of Machine Learning With Multiparametric Magnetic Resonance Imaging of the Breast for Early Prediction of Response to Neoadjuvant Chemotherapy and Survival Outcomes in Breast Cancer Patients.
Tahmassebi A; Wengert GJ; Helbich TH; Bago-Horvath Z; Alaei S; Bartsch R; Dubsky P; Baltzer P; Clauser P; Kapetas P; Morris EA; Meyer-Baese A; Pinker K
Invest Radiol; 2019 Feb; 54(2):110-117. PubMed ID: 30358693
[TBL] [Abstract][Full Text] [Related]
15. From Immunohistochemistry to New Digital Ecosystems: A State-of-the-Art Biomarker Review for Precision Breast Cancer Medicine.
Hacking SM; Yakirevich E; Wang Y
Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884530
[TBL] [Abstract][Full Text] [Related]
16. Computational pathology of pre-treatment biopsies identifies lymphocyte density as a predictor of response to neoadjuvant chemotherapy in breast cancer.
Ali HR; Dariush A; Provenzano E; Bardwell H; Abraham JE; Iddawela M; Vallier AL; Hiller L; Dunn JA; Bowden SJ; Hickish T; McAdam K; Houston S; Irwin MJ; Pharoah PD; Brenton JD; Walton NA; Earl HM; Caldas C
Breast Cancer Res; 2016 Feb; 18(1):21. PubMed ID: 26882907
[TBL] [Abstract][Full Text] [Related]
17. Genomic and transcriptomic analysis of breast cancer identifies novel signatures associated with response to neoadjuvant chemotherapy.
Yin G; Liu L; Yu T; Yu L; Feng M; Zhou C; Wang X; Teng G; Ma Z; Zhou W; Ye C; Zhang J; Ji C; Zhao L; Zhou P; Guo Y; Meng X; Fu Q; Zhang Q; Li L; Zhou F; Zheng C; Xiang Y; Guo M; Wang Y; Wang F; Huang S; Yu Z
Genome Med; 2024 Jan; 16(1):11. PubMed ID: 38217005
[TBL] [Abstract][Full Text] [Related]
18. Prediction of pathologic complete response to neoadjuvant chemotherapy using machine learning models in patients with breast cancer.
Kim JY; Jeon E; Kwon S; Jung H; Joo S; Park Y; Lee SK; Lee JE; Nam SJ; Cho EY; Park YH; Ahn JS; Im YH
Breast Cancer Res Treat; 2021 Oct; 189(3):747-757. PubMed ID: 34224056
[TBL] [Abstract][Full Text] [Related]
19. Tumour-infiltrating lymphocytes (TILs)-related genomic signature predicts chemotherapy response in breast cancer.
Kochi M; Iwamoto T; Niikura N; Bianchini G; Masuda S; Mizoo T; Nogami T; Shien T; Motoki T; Taira N; Tokuda Y; Doihara H; Matsuoka J; Fujiwara T
Breast Cancer Res Treat; 2018 Jan; 167(1):39-47. PubMed ID: 28905250
[TBL] [Abstract][Full Text] [Related]
20. MRI-based machine learning radiomics can predict HER2 expression level and pathologic response after neoadjuvant therapy in HER2 overexpressing breast cancer.
Bitencourt AGV; Gibbs P; Rossi Saccarelli C; Daimiel I; Lo Gullo R; Fox MJ; Thakur S; Pinker K; Morris EA; Morrow M; Jochelson MS
EBioMedicine; 2020 Nov; 61():103042. PubMed ID: 33039708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
